xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li
{"title":"单剂重组人抗血管内皮生长因子(GB222)与替莫唑胺联合治疗复发性世界卫生组织III级和IV级神经胶质瘤患者的I期试验","authors":"xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li","doi":"10.1007/s44194-022-00010-1","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":72735,"journal":{"name":"Current medicine (Cham, Switzerland)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Phase I trial of single-agent recombinant human anti-vascular endothelial growth factor (GB222) followed a combination therapy of GB222 and temozolomide in patients with recurrent WHO grade III and IV glioma\",\"authors\":\"xun kang, Wenbin Ma, Weiping Li, S. Qi, Chongyuan Xu, Xuejun Yang, Liming Wang, Chao Gao, F. Chen, Ce Wang, Z. Kang, Chuanlu Jiang, Wenbin Li\",\"doi\":\"10.1007/s44194-022-00010-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":72735,\"journal\":{\"name\":\"Current medicine (Cham, Switzerland)\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current medicine (Cham, Switzerland)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s44194-022-00010-1\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicine (Cham, Switzerland)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s44194-022-00010-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Phase I trial of single-agent recombinant human anti-vascular endothelial growth factor (GB222) followed a combination therapy of GB222 and temozolomide in patients with recurrent WHO grade III and IV glioma